uBiome: when growth depends on insurance billing that prosecutors call fraud
uBiome began by selling at-home microbiome kits to curious consumers, then pivoted to clinical tests billed to health insurers. Prosecutors allege it billed for unnecessary tests and re-tested old samples to inflate revenue; its co-founders were indicted in 2021.
- Primary cause: Fraud & misreported numbers
- Governance failure
- Founded
- 2012
- Ended
- 2019
- Headquarters
- United States
- Sector
- Health
- Capital raised
- ~$105M
- Peak valuation
- ~$600M (reported)
What happened
Its offices were searched by the FBI in April 2019 and it filed for bankruptcy that September. Its co-founders were indicted on federal fraud charges in 2021; US authorities say they left for Germany, and they have not stood trial.
What uBiome was
Jessica Richman and Zachary Apte founded uBiome in 2012 after a crowdfunding campaign for citizen-science microbiome sequencing. It raised about $105 million and was reportedly valued around $600 million.
To grow revenue, uBiome developed clinical tests that doctors could order and insurers would reimburse. The FBI searched its offices in April 2019, and the company filed for bankruptcy that September. In 2021 a federal grand jury indicted the co-founders on securities and health-care fraud charges, which remain allegations.
Why it failed
- 1
Revenue tied to aggressive insurance billing
Prosecutors allege the company pressured doctors to order tests, billed insurers for tests that weren't medically necessary, and re-tested old samples. Revenue that depends on questionable billing collapses as soon as scrutiny arrives.
- 2
Growth figures used to raise money
According to the indictment, reimbursement revenue was presented to investors to support fundraising. When revenue quality is weak, pressure to show growth can push a company toward misconduct.
- 3
Thin clinical evidence
The clinical usefulness of many microbiome tests was still being established, which made reimbursement harder to justify and billing practices easier to stretch.
The product lesson
In healthcare, who pays shapes the incentives. When the user isn't the payer, growth can come from gaming reimbursement rather than delivering value to patients. Product and growth leaders should understand billing compliance as deeply as they understand conversion rates.
Early warning sign to watch for
Revenue from reimbursement codes grows faster than genuine clinician demand for the product.
Compiled from public reporting, court records, and company statements. Figures are approximate. Where legal proceedings are mentioned, convictions are described as convictions and charges as allegations. Corrections welcome at hello@productmanagement.space.